Narendra Modi's Washington test

Narendra Modi's Washington test

If Modi gets the world’s biggest power right, his pursuit of larger global goals...
Small banks or banks for ‘small’ people?

Small banks or banks for ‘small’ people?

Unless appropriate sub-limits are imposed on loans, there is a serious...

Remain neutral on Bharti Infratel shares with target price of Rs 180: MOFSL

Jan 29 2014, 09:26 IST
Comments 0
Bharti Infratel Ltd's consolidated Ebitda for Q3 grew 5.2% q-o-q to Rs 1,130 crore. Bharti Infratel Ltd's consolidated Ebitda for Q3 grew 5.2% q-o-q to Rs 1,130 crore.
SummaryBharti Infratel’s (BHIN) consolidated Ebitda grew 5.2% q-o-q to Rs 1,130 crore (our estimate Rs 1,100 crore).

Bharti Infratel Ltd's (BHIN) consolidated Ebitda grew 5.2% q-o-q to Rs 1,130 crore (our estimate Rs 1,100 crore). Adjusting for one-off gains from certain settlements with operators, Q3FY14 Ebitda was largely in line at Rs 1,110 crore.

Consolidated revenue grew 1.8% q-o-q to Rs 2,730 crore (our estimate: Rs 2,750 crore), led by a 2.1% increase in rental revenue and a 1.3% increase in energy and other reimbursements.

Ebitda margin improved 133 bps q-o-q to 41.3%, led by cost declines including one-offs. PAT increased 48% q-o-q to Rs 410 crore (our estimate: Rs 353 crore) due to higher reported Ebitda and other income.

Roll-out intensity increased q-o-q, with co-location additions growing from 1,959 in Q2FY14 to 3,373 in Q3FY14. Towers/co-locations grew 0.4/2.1% q-o-q. Average sharing factor grew from 1.93 in Q2FY14 to 1.96 in Q3FY14.

While BHIN is well positioned, with one of the top-3 GSM incumbents as anchor tenant across its portfolio, network rollout intensity remains low. We are upgrading our Ebitda estimates by 1-2%. The stock trades at 19.1x FY15E EPS and at an EV of 6.1x FY15E Ebitda. We are rolling forward our valuations to December 2014. Maintain ‘neutral’ with a revised target price of Rs 180 (Rs 56 earlier), based on SOTP/DCF.

-MOFSL

Ads by Google

More from Money & Funds

Reader´s Comments
| Post a Comment
Please Wait while comments are loading...